Earnings Call · Q4 FY2025·2026-03-26

Q4 25EPS +10.05%·Rev n/aQ3 25EPS +35.29%·Rev n/aQ2 25EPS -30.77%·Rev n/aQ1 25EPS +12.73%·Rev n/a⚠ consensus missing

Acumen Pharmaceuticals, Inc. ABOS

Alex Braun — Head of Investor Relations

Daniel O'Connell — Chief Executive Officer

James Doherty — President and Chief Development Officer

Matt Zuga — Chief Financial Officer

−3.0%1d on move date−1.3% vs SPY3d−16.7%5d−3.0%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ABOS calls or request research access.

More ABOS calls Browse calls Request research access